Description

The injectable pen is the world’s most advanced weight-loss solution. Max—widely known as “Mounjaro”—is a modern appetite-suppressing medication that leads to significant weight loss. It works by mimicking the action of GLP-1 and GIP receptors—natural hormones that induce a feeling of fullness, allowing a person to feel satisfied after consuming much smaller portions of food.

The 20, 40, and 60 mg kits include one pen, 12 disposable needles, and instructions for use.

Each pen contains 20, 40, or 60 mg of the active substance, which can be administered as four full 10 mg doses or in increments of 2.5 mg, 5 mg, 7.5 mg, or 10 mg.

The recommended dosage is 2.5 mg for the first 4 weeks, followed by 5 mg for the next 4 weeks. After 8 weeks, the weekly dosage may be increased to 7.5 mg or 10 mg if necessary.

Always consult a doctor, nurse, or pharmacist before using a new medication.

What are the benefits of the Max peptide?
Tirzemax is used for type 2 diabetes. It differs from other similar medications—such as GLP-1 receptor agonists—in the following ways:

It effectively lowers blood sugar levels in people with type 2 diabetes.
It helps keep blood sugar under control, protecting against various complications.
It promotes weight loss and is well-suited for individuals who are overweight. Improves metabolism, helping to burn fat and prevent its accumulation.
Reduces the risk of heart disease in people with diabetes.
Helps normalize blood pressure.
Supports normal kidney function.
Reduces the risk of diabetes complications such as retinopathy and neuropathy.
Improves the overall well-being of people with diabetes.
Tirzemax Clinical Trials: Summary
Tirzemax has been evaluated in several clinical studies. These showed that the drug helps manage type 2 diabetes and promotes weight loss in overweight individuals.

What the tests showed:
SURPASS-1: Over 4,500 people with diabetes and high blood sugar participated in this Phase 3 study. Those taking Tirzemax achieved better blood sugar normalization compared to those treated with other type 2 diabetes medications. Participants also lost weight.
SURMOUNT-1: This trial involved 478 overweight individuals without diabetes. All participants lost weight after taking the peptide.
SURPASS-2: This Phase 3 study involved 1,879 previously untreated patients with type 2 diabetes. The results confirmed that the drug effectively lowers blood sugar levels.
Another clinical study involving 2,121 people with diabetes and high blood sugar compared treatment with insulin versus Tirzemax. Patients taking Tirzemax experienced a greater reduction in blood sugar levels compared to those using insulin. Additionally, the first group showed a decrease in body weight.

Usage:
Dosage depends on the patient’s specific needs and goals; the drug is typically administered at a dose of 2.5 mg, with the possibility of increasing it to 5 mg–10 mg after the fourth week if necessary.

Additional administration instructions: 1 unit corresponds to 1 click on the dial. Administer into the abdominal area or the front of the thigh.

After injecting the drug, wait 10 seconds before withdrawing the needle. Rotating the injection site is recommended.

The 20 mg pen contains 200 units of 100 mcg each.

1 click = 100 mcg
10 clicks = 1 mg
25 clicks = 2.5 mg
50 clicks = 5 mg
The 40 mg pen contains 200 units of 200 mcg each.

1 click = 200 mcg
10 clicks = 2 mg
13 clicks = 2.5 mg
25 clicks = 5 mg
38 clicks = 7.5 mg
50 clicks = 10 mg
Composition:
Tirzemax

Attention! The information on this site is for informational purposes only; the product is not a medicinal drug. Packaging appearance may be changed by the manufacturer without prior notice.

The product is intended for research purposes only. The information was gathered through numerous studies and analyses conducted over many years and is not intended for the diagnosis, treatment, or prevention of any disease.